Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with a higher risk of developing luminal-like breast cancer subtypes and other subtypes.
Women who developed a cardiovascular disease or type 2 diabetes were at a higher risk of developing breast cancer post menopause, a recent study found.
Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.